MedTrace Logo

Allogeneic γδT Cells in Glioblastoma

NCT07144735 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2025-08-27

No results posted yet for this study

Summary

This first-in-human clinical study aims to evaluate the safety and feasibility of locally delivered, allogeneic γδ T cells (genetically edited with ARIH1 and BCL11b knockout, designated ABOUT γδT cells) in patients with glioblastoma multiforme (GBM). The engineered effector cells are delivered via localized administration to selectively target and eliminate residual GBM cells. ABOUT: ARIH1 and BCL11b knockOUT γδ T cells.

Conditions

  • Glioblastoma (GBM)
  • Glioblastoma Multiforme (GBM)

Interventions

DRUG

Allogeneic γδ T (ABOUT) cells

Allogeneic γδ T cells genetically edited to knockout the ARIH1 and BCL11b genes.

Sponsors & Collaborators

  • Peking University

    collaborator OTHER

  • Changping Laboratory

    collaborator OTHER

  • Peking University Third Hospital

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-01
Primary Completion
2027-12-31
Completion
2030-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07144735 on ClinicalTrials.gov